DPI-3290 was discovered by scientists at Burroughs Wellcome and licensed to Delta Pharmaceutical [1] and is a drug that is used in scientific research. It is a potent analgesic drug, [2] which produces little respiratory depression. [3] DPI-3290 acts as an agonist at both μ-and δ-opioid receptor, with an IC50 of 6.2nM at μ and 1.0nM at δ. [4]

DPI-3290 is an agonist with high-affinity binding characteristics at opioid receptors that does not distinguish between the δ-, μ-, or κ-subtypes. This is in contrast to morphine or fentanyl, which are relatively selective agonists with high-affinity binding at the μ-subtype of the opioid receptor.

(+)-3- ( (alphaR)-alpha- ( (2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N- (3-fluorophenyl)-N-methylbenzamide | C30H34FN3O2 | CID 9826770 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

2003年12月1日 · Intravenous bolus doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg had no effect on antinociception mediated by alfentanil (2 μg/kg/min i.v.) but reduced hypercapnia by approximately 50%. Results from these studies demonstrate the equivalent antinociceptive efficacy of DPI-3290, morphine, and fentanyl but dramatic differences in the ...

Intravenous bolus doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg had no effect on antinociception mediated by alfentanil (2 microg/kg/min i.v.) but reduced hypercapnia by approximately 50%. Results from these studies demonstrate the equivalent antinociceptive efficacy of DPI-3290, morphine, and fentanyl but dramatic differences in the ...

DPI-3290 (Org 41793) is a potent and specific opioid receptors agonist with K i values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively。 DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity [1] .

Separation of the desired enantiomer (V) was achieved through recrystallization of the salt with di-p-toluoyl-D-tartaric acid, followed by liberation of the base with NaOH. Alternatively, a chiral …

DPI-3290 is a drug which is used in scientific research. It is a potent analgesic drug, [1] which produces little respiratory depression. [2] DPI-3290 acts as an agonist at both μ-and δ-opioid receptors, with an IC50 of 6.2nM at μ and 1.0nM at δ. [3] References

Compound (+)-3-((α-R)-α-((2 S,5 R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), is one of a series of novel centrally acting agents with potent antinociceptive activity that binds specifically and with high affinity to opioid receptors.